Sinemet is a pharmaceutical drug engineered by Merck that combines Carbidopa (a peripheral enzymatic inhibitor of DOPA decarboxylase) and Levodopa (an agent that crosses the blood-brain barrier to increase central concentrations of dopamine); hence it is frequently referred to as “Carbidopa-Levodopa.” The drug was initially approved by the U.S. FDA in 1988 for the treatment …
Requip (Ropinirole) is a drug initially approved in 1997 by the United States FDA for the treatment of [early or advanced-stage] idiopathic Parkinson’s disease. In the management of Parkinson’s disease, Requip can be utilized either as: a standalone agent or as an adjunct to L-DOPA. After its initial approval for the attenuation of Parkinson’s symptoms, …
Mirapex (Pramipexole) is a medication that was approved by the FDA in 1997 for the treatment of idiopathic (early-stage and advanced) Parkinson’s disease. Analysis of the drug’s pharmacodynamics reveals its function as a mixed partial/full dopamine agonist, with highest affinity for: D3 receptors, D2 receptors (D2S and D2L), and D4 receptors (in that order). To …